Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery
Sanju Dhawan
University Institute of Pharmaceutical Sciences (UGC Center of Advanced Studies), Panjab University, Chandigarh, India
Search for more papers by this authorRishi Kapil
University Institute of Pharmaceutical Sciences (UGC Center of Advanced Studies), Panjab University, Chandigarh, India
Search for more papers by this authorBhupinder Singh
University Institute of Pharmaceutical Sciences (UGC Center of Advanced Studies), Panjab University, Chandigarh, India
Search for more papers by this authorSanju Dhawan
University Institute of Pharmaceutical Sciences (UGC Center of Advanced Studies), Panjab University, Chandigarh, India
Search for more papers by this authorRishi Kapil
University Institute of Pharmaceutical Sciences (UGC Center of Advanced Studies), Panjab University, Chandigarh, India
Search for more papers by this authorBhupinder Singh
University Institute of Pharmaceutical Sciences (UGC Center of Advanced Studies), Panjab University, Chandigarh, India
Search for more papers by this authorAbstract
Objective This study aims at formulating solid lipid nanoparticles (SLNs) of quercetin, a natural flavonoid with established antioxidant activity, for intravenous administration in order to improve its permeation across the blood–brain barrier into the CNS, and eventually to improve the therapeutic efficacy of this molecule in Alzheimer's disease.
Methods The SLNs of quercetin were formulated using Compritol as the lipid and Tween 80 as the surfactant through a microemulsification technique, and optimized employing a 32 central composite design (CCD). Selection of the optimized SLN formulation, using brute-force methodology and overlay plots, was based on its efficiency of entrapping quercetin inside the lipophilic core, particle size, surface charge potential and ability of the SLNs to release the entrapped drug completely. The optimized formulation was subjected to various in-vivo behavioral and biochemical studies in Wistar rats.
Key findings The optimized formulation exhibited a particle size of less than 200 nm, 85.73% drug entrapment efficiency and a zeta potential of 21.05 mV. In all the in-vivo behavioral and biochemical experiments, the rats treated with SLN-encapsulated quercetin showed markedly better memory-retention vis-à-vis test and pure quercetin-treated rats.
Conclusions The studies demonstrated successful targeting of the potent natural antioxidant, quercetin, to brain as a novel strategy having significant therapeutic potential to treat Alzheimer's disease.
References
- 1 Behl C. The search for novel avenues for the therapy and prevention of Alzheimer's disease. Drug News Perspect 2006; 19: 5–12.
- 2 Pietrzik C, Behl C. Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int J Exp Pathol 2005; 86: 173–185.
- 3 Mott RT, Hulette CM. Neuropathology of Alzheimer's disease. Neuroimaging Clin N Am 2005; 15: 755–765.
- 4 Dhawan K, Dhawan S. The importance of Passionflower in therapeutics – some folklore medicinal use and the latest pharmacological studies. In: JN Govil, VK Singh, eds. Recent Progress in Medicinal Plants. Houstan, USA: Texas: Stadium press, LLC, 2006.
- 5 Dhawan K et al. Passiflora: a review update. J Ethnopharmacol 2004; 94: 1–23.
- 6 Dhawan K et al. Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic. J Pharm Pharm Sci 2003; 6: 215–222.
- 7 Behl C, Moosmann B. Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds. Biol Chem 2002; 383: 521–536.
- 8 Huber A et al. Neuroprotective therapies for Alzheimer's disease. Curr Pharm Des 2006; 12: 705–717.
- 9 Rice-Evans CA et al. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic Res 1995; 22: 375–383.
- 10 Hu P et al. Quercetin relieves chronic lead exposure-induced impairment of synaptic plasticity in rat dentate gyrus in vivo. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 43–51.
- 11 Kitagawa S et al. Enhanced skin delivery of quercetin by microemulsion. J Pharm Pharmacol 2009; 61: 855–860.
- 12 Wu TH et al. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 2008; 346: 160–168.
- 13 Bondi ML et al. Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine 2010; 5: 25–32.
- 14 Wong HL et al. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev 2010; 62: 503–517.
- 15 Singh B et al. Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics. Acta Pharm 2009; 59: 1–13.
- 16 Li H et al. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Controlled Release 2009; 133: 238–244.
- 17 Singh B, Singh S. A compreshensive computer program for study of drug release kinetics from compressed matrices. Indian J Pharm Sci 1998; 60: 313–316.
- 18 Singh B et al. Correction of raw dissolution data for loss of drug during sampling. Indian J Pharm Sci 1997; 59: 196–199.
- 19 Sashmal S et al. Design and optimization of NSAID loaded nanoparticles. Pak J Pharm Sci 2007; 20: 157–162.
- 20 Reagan-Shaw S et al. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659–661.
- 21 Kumar A et al. Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type. Pharmacol Rep 2007; 59: 274–283.
- 22 Hemb M et al. Effects of early malnutrition, isolation and seizures on memory and spatial learning in the developing rat. Int J Dev Neurosci 2010; 28: 303–307.
- 23 Skirzewski M et al. Acute lecozotan administration increases learning and memory in rats without affecting anxiety or behavioral depression. Pharmacol Biochem Behav 2010; 95: 325–330.
- 24 Kumar A et al. Protective effect of curcumin (Curcuma longa), against aluminium toxicity: possible behavioral and biochemical alterations in rats. Behav Brain Res 2009; 205: 384–390.
- 25 Gaur V et al. Protective effect of naringin against ischemic reperfusion cerebral injury: possible neurobehavioral, biochemical and cellular alterations in rat brain. Eur J Pharmacol 2009; 616: 147–154.
- 26 Kumar P, Kumar A. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations. Eur J Pharmacol 2009; 615: 91–101.
- 27 Daniel WW. Biostatistics: A Foundation for Analysis in the Health Sciences. 7th Edition edn. Singapore: John Wiley & Sons, 2000.
- 28 Kaur IP et al. Potential of solid lipid nanoparticles in brain targeting. J Controlled Rel 2008; 127: 97–109.
- 29 Passerini N et al. Evaluation of solid lipid microparticles produced by spray congealing for topical application of econazole nitrate. J Pharm Pharmacol 2009; 61: 559–567.
- 30 Hu L et al. Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery. Pharmazie 2010; 65: 585–587.
- 31 Mulik RS et al. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm 2010; 398: 190–203.
- 32 Blasi P et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007; 59: 454–477.
- 33 Bhalekar MR et al. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech 2009; 10: 289–296.
- 34 Abdelbary G, Fahmy RH. Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech 2009; 10: 211–219.
- 35 Singh B, Ahuja N. Development of controlled-release buccoadhesive hydrophilic matrices of diltiazem hydrochloride: optimization of bioadhesion, dissolution, and diffusion parameters. Drug Dev Ind Pharm 2002; 28: 431–442.
- 36 Singh B et al. Optimizing drug delivery systems using systematic ‘design of experiments.’ Part II: retrospect and prospects. Crit Rev Ther Drug Carrier Syst 2005; 22: 215–294.
- 37 Singh B et al. Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology. AAPS PharmSciTech 2006; 7: E1–E10.
- 38 Singh B, Agarwal R. Design development and optimization of controlled release microcapsules of diltiazem hydrochloride. Indian J Pharm Sci 2002; 64: 378–385.
- 39 Singh B et al. Optimizing drug delivery systems using systematic ‘design of experiments.’ Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst 2005; 22: 27–105.
- 40 Singh B, Ahuja N. Response surface optimization of drug delivery systems. In: NK Jain, ed. Progress in Controlled and Novel Drug Delivery Systems. New Delhi: CBS Publishers, 2004: 470–509.
- 41 Singh B et al. Formulation optimization of hydrodynamically balanced oral controlled release bioadhesive tablets of tramadol hydrochloride. Sci Pharm 2010; 78: 303–323.
- 42 Thakkar H et al. Enhanced retention of celecoxib-loaded solid lipid nanoparticles after intra-articular administration. Drugs R D 2007; 8: 275–285.
- 43 Jain SK et al. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul 2008; 25: 289–297.
- 44 Tangsuphoom N, Coupland JN. Effect of pH and ionic strength on the physicochemical properties of coconut milk emulsions. J Food Sci 2008; 73: E274–E280.
- 45 Yeung A et al. Shear-induced coalescence of emulsified oil drops. J Colloid Interface Sci 2003; 265: 439–443.
- 46 Subedi RK et al. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci 2009; 37: 508–513.
- 47 Hu L et al. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech 2010; 11: 582–587.
- 48 Liu G et al. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta 2005; 1741: 246–252.
- 49 Liu G et al. Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett 2009; 455: 187–190.
- 50 Kurakhmaeva KB et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 2009; 17: 564–574.
- 51 Ren T et al. Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles. J Biomater Sci Polym Ed 2009; 20: 1369–1380.
- 52 Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target 2005; 13: 179–187.
